#royalty-model

Protagonist Therapeutics Stock: Opt-Out Turned A Biotech Royalty Compounder (NASDAQ:PTGX)

Protagonist Therapeutics has successfully transitioned into a royalty-driven biotech company, now boasting two FDA-approved drugs. This strategic shift positions PTGX as a compelling investment opportunity, leveraging its intellectual property for sustained revenue generation.